Teva's Igalmi Approved for At-Home Use to Treat Patients With Agitation Due to Mental Disorders

MT Newswires Live11-16

Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals US affiliate said Monday that the US Food and Drug Administration has approved at-home use of Igalmi sublingual film to treat agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders in adults.

The company said the approval makes Igalmi the first FDA-approved treatment for the disorders that can be used at home.

Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders affects 25% to 40% of patients with those conditions, Teva said, adding that up to 21% of cases can result in an emergency department visit or hospitalization.

Teva owns Igalmi as part of its October acquisition of BioXcel Therapeutics' assets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment